arrow
Q

Qingsong Gao

Chinese Academy of Engineering Physics
H指数:30
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseases

ASH HematOmics计划支持血液系统疾病中基因组学和临床数据的整合分析。

Blood
IF23.1
2026-04-080
OAAI
Deregulation of FOXF1/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia

t(14;16)(q32;q24)对FOXF1/FENDRR的去调控定义了一种高风险系模糊白血病亚型

Blood
IF23.1
2026-03-100
OA
DHODH as a Targetable Metabolic Achilles' Heel for chemo-resistant B-ALL

DHODH作为抗化疗b-all的可靶向代谢致命弱点

Blood
IF23.1
2026-01-290
PRE
DIVERGENT MEDULLOBLASTOMA CHROMATIN STATES DISCLOSE KDM2B AS A SELECTIVE DEPENDENCY

分化型髓母细胞瘤染色质状态揭示KDM2B为选择性依赖

2025-11-010
OAAI
Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage ambiguous leukemia

维奈克拉联合吉特利替尼在FLT3突变BCL11B-a谱系模糊性白血病的体外模型中是有效的。

Blood
IF23.1
2025-08-180
OA
Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features

B细胞急性淋巴细胞白血病的多能谱系潜能与特定的细胞起源和临床特征相关。

2025-06-270
PRE
Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies

ETV6::RUNX1或高超二倍体B-ALL患者在接受St. Jude Total Therapy XV/XVI研究治疗后结果

BLOOD
IF23.1
2025-01-093
PRE
Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk

儿童 γ δ t-all的生物学和临床分析将LMO2/STAG2重排确定为极高风险

2024-06-242
PRE
DIVERGENT MEDULLOBLASTOMA CHROMATIN STATES DISCLOSE KDM2B AS A NOVEL ONCOGENIC DEPENDENCY
2024-06-180
OAAI